The MF author is evidently confused about the disease settings. Tarceva failed in first-line NSCLC as an addition to standard chemo, but it succeeded as monotherapy in the second line.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.